Terms: = Leukemia AND FGFR1OP, FOP, 11116, ENSG00000213066
23 results:
1. Fear of progression in parents of childhood cancer survivors: prevalence and associated factors.
Peikert ML; Inhestern L; Krauth KA; Escherich G; Rutkowski S; Kandels D; Schiekiera LJ; Bergelt C
J Cancer Surviv; 2022 Aug; 16(4):823-833. PubMed ID: 34302272
[TBL] [Abstract] [Full Text] [Related]
2. Fear of progression in parents of childhood cancer survivors: A dyadic data analysis.
Peikert ML; Inhestern L; Krauth KA; Escherich G; Rutkowski S; Kandels D; Bergelt C
Psychooncology; 2020 Oct; 29(10):1678-1685. PubMed ID: 32779255
[TBL] [Abstract] [Full Text] [Related]
3. Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation.
Thiele S; Goebel S; Kröger N; Pedersen A
Psychooncology; 2020 Aug; 29(8):1248-1254. PubMed ID: 32323380
[TBL] [Abstract] [Full Text] [Related]
4. miR-16-2* Interferes with WNT5A to Regulate Osteogenesis of Mesenchymal Stem Cells.
Duan L; Zhao H; Xiong Y; Tang X; Yang Y; Hu Z; Li C; Chen S; Yu X
Cell Physiol Biochem; 2018; 51(3):1087-1102. PubMed ID: 30476907
[TBL] [Abstract] [Full Text] [Related]
5. Early clinical observations on the use of imatinib mesylate in fop: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract] [Full Text] [Related]
6. Fear of Progression in Outpatients With Chronic Myeloid leukemia on Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2016 Mar; 43(2):190-7. PubMed ID: 26906130
[TBL] [Abstract] [Full Text] [Related]
7. Involvement of the Wnt signaling pathway in feeder‑free culture of human induced pluripotent stem cells.
Tomizawa M; Shinozaki F; Motoyoshi Y; Sugiyama T; Yamamoto S; Ishige N
Mol Med Rep; 2015 Nov; 12(5):6797-800. PubMed ID: 26398905
[TBL] [Abstract] [Full Text] [Related]
8. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee JY; Hong WJ; Majeti R; Stearns T
PLoS One; 2014; 9(3):e92641. PubMed ID: 24658090
[TBL] [Abstract] [Full Text] [Related]
9. Functional characterization of a novel fgfr1op-RET rearrangement in hematopoietic malignancies.
Bossi D; Carlomagno F; Pallavicini I; Pruneri G; Trubia M; Raviele PR; Marinelli A; Anaganti S; Cox MC; Viale G; Santoro M; Di Fiore PP; Minucci S
Mol Oncol; 2014 Mar; 8(2):221-31. PubMed ID: 24315414
[TBL] [Abstract] [Full Text] [Related]
10. fop is a centriolar satellite protein involved in ciliogenesis.
Lee JY; Stearns T
PLoS One; 2013; 8(3):e58589. PubMed ID: 23554904
[TBL] [Abstract] [Full Text] [Related]
11. 3-methoxyapigenin modulates β-catenin stability and inhibits Wnt/β-catenin signaling in Jurkat leukemic cells.
Chuang KA; Lieu CH; Tsai WJ; Huang WH; Lee AR; Kuo YC
Life Sci; 2013 Apr; 92(12):677-86. PubMed ID: 23333831
[TBL] [Abstract] [Full Text] [Related]
12. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.
Ballerini P; Struski S; Cresson C; Prade N; Toujani S; Deswarte C; Dobbelstein S; Petit A; Lapillonne H; Gautier EF; Demur C; Lippert E; Pages P; Mansat-De Mas V; Donadieu J; Huguet F; Dastugue N; Broccardo C; Perot C; Delabesse E
Leukemia; 2012 Nov; 26(11):2384-9. PubMed ID: 22513837
[TBL] [Abstract] [Full Text] [Related]
13. Myeloproliferative disorders with t(8;9)(p12;q33): a case report and review of the literature.
Hu S; He Y; Zhu X; Li J; He H
Pediatr Hematol Oncol; 2011 Mar; 28(2):140-6. PubMed ID: 21214407
[TBL] [Abstract] [Full Text] [Related]
14. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
Mozziconacci MJ; Carbuccia N; Prebet T; Charbonnier A; Murati A; Vey N; Chaffanet M; Birnbaum D
Leuk Res; 2008 Aug; 32(8):1304-8. PubMed ID: 18096225
[TBL] [Abstract] [Full Text] [Related]
15. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer.
Mano Y; Takahashi K; Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Tsuchiya E; Nakamura Y; Daigo Y
Cancer Sci; 2007 Dec; 98(12):1902-13. PubMed ID: 17888034
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.
Zeiser R; Spyridonidis A; Wäsch R; Ihorst G; Grüllich C; Bertz H; Finke J
Leukemia; 2005 May; 19(5):814-21. PubMed ID: 15772700
[TBL] [Abstract] [Full Text] [Related]
17. Clinical variability of patients with the t(6;8)(q27;p12) and fgfr1op-FGFR1 fusion: two further cases.
Vizmanos JL; Hernández R; Vidal MJ; Larráyoz MJ; Odero MD; Marín J; Ardanaz MT; Calasanz MJ; Cross NC
Hematol J; 2004; 5(6):534-7. PubMed ID: 15570299
[TBL] [Abstract] [Full Text] [Related]
18. Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells.
Saegusa M; Hashimura M; Kuwata T; Hamano M; Okayasu I
Am J Pathol; 2004 May; 164(5):1739-49. PubMed ID: 15111320
[TBL] [Abstract] [Full Text] [Related]
19. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.
Macdonald D; Reiter A; Cross NC
Acta Haematol; 2002; 107(2):101-7. PubMed ID: 11919391
[TBL] [Abstract] [Full Text] [Related]
20. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
[TBL] [Abstract] [Full Text] [Related]
[Next]
